Download Files:
Roginolisib (hemifumarate)
SKU
HY-135827A-10 mg
Category Reference compound
Tags Cancer; Inflammation/Immunology, PI3K, PI3K/Akt/mTOR
$240 – $1,900
Products Details
Product Description
– Roginolisib (MSC2360844) hemifumarate is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib hemifumarate shows highly selective against a panel of 278 additional kinases[1].
Web ID
– HY-135827A
Storage Temperature
– 4°C (Powder, sealed storage, away from moisture)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C26H27FN4O5S.1/2C4H4O4
References
– [1]Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233.
CAS Number
– 1621688-31-0
Molecular Weight
– 584.62
Compound Purity
– 99.95
SMILES
– O=C(C1=NN(C2=CC=C(CN3CCOCC3)C=C2)C(C4=CC=CC(F)=C45)=C1CS5(=O)=O)N6CCOCC6.OC(/C=C/C(O)=O)=O.[1/2]
Clinical Information
– No Development Reported
Research Area
– Cancer; Inflammation/Immunology
Solubility
– DMSO : 100 mg/mL (ultrasonic)
Target
– PI3K
Isoform
– PI3Kδ
Pathway
– PI3K/Akt/mTOR
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.